My thought are.
No trifecta but a very good Double.
1/Response rate was Higher with sirt by 7.4%
2/Both the side effect profile and QUALITY OF LIFE was much better over time in the sirt group.
3/ if patient Re not tolerant or have contraindications for Sorafenib therapy there are currently no standard of care .
Paragraph 2 an 3 is the key for me.
Yes i get it the primary end point did not show an overall survival superiority
I the end quality of life is far more important.
Glta
Sirt result
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $74.27M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 17.5¢ | 17.5¢ | $17.5K | 100K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 6471053 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 1529287 | 14 |
View Market Depth
| Last trade - 10.08am 30/07/2024 (20 minute delay) ? |
| SRX (ASX) Chart |